223 related articles for article (PubMed ID: 25990246)
1. Identification of targets for rational pharmacological therapy in childhood craniopharyngioma.
Gump JM; Donson AM; Birks DK; Amani VM; Rao KK; Griesinger AM; Kleinschmidt-DeMasters BK; Johnston JM; Anderson RC; Rosenfeld A; Handler M; Gore L; Foreman N; Hankinson TC
Acta Neuropathol Commun; 2015 May; 3():30. PubMed ID: 25990246
[TBL] [Abstract][Full Text] [Related]
2. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
[TBL] [Abstract][Full Text] [Related]
3. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
Robinson LC; Santagata S; Hankinson TC
Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
[TBL] [Abstract][Full Text] [Related]
4. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
Hengartner AC; Prince E; Vijmasi T; Hankinson TC
Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
[TBL] [Abstract][Full Text] [Related]
5. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional analyses of adult and pediatric adamantinomatous craniopharyngioma reveals similar expression signatures regarding potential therapeutic targets.
Prince E; Whelan R; Donson A; Staulcup S; Hengartner A; Vijmasi T; Agwu C; Lillehei KO; Foreman NK; Johnston JM; Massimi L; Anderson RCE; Souweidane MM; Naftel RP; Limbrick DD; Grant G; Niazi TN; Dudley R; Kilburn L; Jackson EM; Jallo GI; Ginn K; Smith A; Chern JJ; Lee A; Drapeau A; Krieger MD; Handler MH; Hankinson TC;
Acta Neuropathol Commun; 2020 May; 8(1):68. PubMed ID: 32404202
[TBL] [Abstract][Full Text] [Related]
7. High expression levels of CXCL12 and CXCR4 predict recurrence of adamanti-nomatous craniopharyngiomas in children.
Gong J; Zhang H; Xing S; Li C; Ma Z; Jia G; Hu W
Cancer Biomark; 2014; 14(4):241-51. PubMed ID: 24934367
[TBL] [Abstract][Full Text] [Related]
8. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.
Donson AM; Apps J; Griesinger AM; Amani V; Witt DA; Anderson RCE; Niazi TN; Grant G; Souweidane M; Johnston JM; Jackson EM; Kleinschmidt-DeMasters BK; Handler MH; Tan AC; Gore L; Virasami A; Gonzalez-Meljem JM; Jacques TS; Martinez-Barbera JP; Foreman NK; Hankinson TC;
J Neuropathol Exp Neurol; 2017 Sep; 76(9):779-788. PubMed ID: 28859336
[TBL] [Abstract][Full Text] [Related]
9. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
[TBL] [Abstract][Full Text] [Related]
10. Expression of the epidermal growth factor system in human middle ear cholesteatoma.
Thorup MB; Munk M; Poulsen SS; Gaihede M; Nexo E; Sorensen BS; Ovesen T
Acta Otolaryngol; 2014 Feb; 134(2):124-34. PubMed ID: 24256036
[TBL] [Abstract][Full Text] [Related]
11. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.
Wu Z; Doondeea JB; Gholami AM; Janning MC; Lemeer S; Kramer K; Eccles SA; Gollin SM; Grenman R; Walch A; Feller SM; Kuster B
Mol Cell Proteomics; 2011 Dec; 10(12):M111.011635. PubMed ID: 21955398
[TBL] [Abstract][Full Text] [Related]
12. Adamantinomatous craniopharyngioma in the molecular age and the potential of targeted therapies: a review.
Whelan R; Hengartner A; Folzenlogen Z; Prince E; Hankinson TC
Childs Nerv Syst; 2020 Aug; 36(8):1635-1642. PubMed ID: 32440897
[TBL] [Abstract][Full Text] [Related]
13. Integrative analyses identify HIF-1α as a potential protective role with immune cell infiltration in adamantinomatous craniopharyngioma.
Gao Q; Luo J; Pan J; Zhang L; Song D; Zhang M; Xu D; Guo F
Front Immunol; 2022; 13():949509. PubMed ID: 36091021
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma.
Andoniadou CL; Gaston-Massuet C; Reddy R; Schneider RP; Blasco MA; Le Tissier P; Jacques TS; Pevny LH; Dattani MT; Martinez-Barbera JP
Acta Neuropathol; 2012 Aug; 124(2):259-71. PubMed ID: 22349813
[TBL] [Abstract][Full Text] [Related]
15. Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.
Skrzypski M; Dziadziuszko R; Jassem E; Szymanowska-Narloch A; Gulida G; Rzepko R; Biernat W; Taron M; Jelitto-Górska M; Marjański T; Rzyman W; Rosell R; Jassem J
Clin Lung Cancer; 2013 Nov; 14(6):666-673.e2. PubMed ID: 23870818
[TBL] [Abstract][Full Text] [Related]
16. SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma.
Carreno G; Boult JKR; Apps J; Gonzalez-Meljem JM; Haston S; Guiho R; Stache C; Danielson LS; Koers A; Smith LM; Virasami A; Panousopoulos L; Buchfelder M; Jacques TS; Chesler L; Robinson SP; Martinez-Barbera JP
Endocr Relat Cancer; 2019 Mar; 26(3):355-366. PubMed ID: 30645190
[TBL] [Abstract][Full Text] [Related]
17. Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas.
Gomes DC; Jamra SA; Leal LF; Colli LM; Campanini ML; Oliveira RS; Martinelli CE; Elias PC; Moreira AC; Machado HR; Saggioro F; Neder L; Castro M; Antonini SR
Eur J Endocrinol; 2015 May; 172(5):603-8. PubMed ID: 25693592
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of ERBB family mRNA expression in breast carcinomas.
Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
[TBL] [Abstract][Full Text] [Related]
19. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
[TBL] [Abstract][Full Text] [Related]
20. Expression of SRY-related HMG Box Transcription Factors (Sox) 2 and 9 in Craniopharyngioma Subtypes and Surrounding Brain Tissue.
Thimsen V; John N; Buchfelder M; Flitsch J; Fahlbusch R; Stefanits H; Knosp E; Losa M; Buslei R; Hölsken A
Sci Rep; 2017 Nov; 7(1):15856. PubMed ID: 29158570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
